Trending archive
Every article that has appeared in Trending stays here. Search by title, journal, author or PMID, and narrow by date.
433 articles
July 202624
Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial.
This phase 2 randomized trial evaluated the long-term efficacy and safety of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) over five years.
AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group.
The AAML1831 phase III trial assessed the efficacy of CPX-351 versus standard daunorubicin/cytarabine (DA) in children and young adults with newly diagnosed AML.
Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study.
This phase I multicenter study evaluated the efficacy and safety of rocbrutinib, a fourth-generation BTK inhibitor, in 45 Chinese patients with relapsed or refractory non-GCB DLBCL.
Hemophagocytic lymphohistiocytosis and posterior reversible encephalopathy syndrome during BRAF/MEK inhibitor therapy following immune checkpoint blockade in metastatic melanoma: a case report.
A 61-year-old female with BRAF V600K-mutant metastatic melanoma developed hemophagocytic lymphohistiocytosis (HLH) after sequential treatment with immune checkpoint inhibitors and BRAF/MEK inhibitors.
Fludarabine, Busulfan, Thiotepa, and Melphalan: A Novel Low-Toxicity Myeloablative Conditioning Regimen for Haploidentical HSCT in Children and Adolescents Aged ≥7 Years With Transfusion-Dependent β-Thalassemia.
This prospective clinical trial evaluated a novel low-toxicity myeloablative conditioning regimen (F-BMT) in 29 children and adolescents aged ≥7 years with transfusion-dependent β-thalassemia undergoing haploidentical…
Hematopoietic Recovery and Safety Following Early Romiplostim Administration After Pediatric HSCT: A Prospective Randomized Pilot Study.
This randomized controlled trial evaluated the safety and effects of early romiplostim administration in 32 children undergoing hematopoietic stem cell transplantation (HSCT).
Occult brodifacoum poisoning presenting as a massive intramuscular hematoma.
A 56-year-old man presented with significant swelling in his right thigh, which had developed over nine days without any recent trauma.
Lymph Node Cytology Raising Suspicion for Evolving Secondary Hemophagocytic Lymphohistiocytosis in a Case of Mendelian Susceptibility to Mycobacterial Disease.
A 4-month-old male infant with genetically confirmed Mendelian susceptibility to mycobacterial disease presented at 22 months with generalized lymphadenopathy, massive splenomegaly, bicytopenia, and high-grade fever.
Genomic Diversity and Clinical Variability in Pediatric Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Series.
Three pediatric patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) presented with skin-limited disease. They exhibited significant molecular heterogeneity, including known and novel gene fusions.
Multiple myeloma diagnosed after contrast-enhanced computed tomography without renal complications: a case report with literature review.
A 77-year-old woman presented with numbness of the right lower lip, leading to a panoramic radiography that revealed a radiolucent lesion in the right mandible.
Collision Tumor of Merkel Cell Carcinoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Cytological and Flow Cytometric Diagnostic Pitfall.
A 68-year-old male presented with right axillary lymphadenomegaly. Fine-needle cytology revealed a population of intermediate-sized lymphoid cells and larger plasmacytoid cells.
Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.
The RACE study evaluated the addition of eltrombopag to standard immunosuppressive treatment in 197 treatment-naive patients with severe aplastic anemia.
Liver Transplantation in a Patient With Fulminant Failure and Bone Marrow Aplasia Due to Methimazole: A Case Report.
A 37-year-old man with Graves' disease developed fulminant hepatitis and bone marrow aplasia after four years of methimazole treatment.
Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
The FELIX study evaluated the efficacy of obecabtagene autoleucel (obe-cel) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) compared to historical controls.
Clonal haematopoiesis of indeterminate potential and epigenetic age acceleration: Systematic review and meta-analysis.
This systematic review and meta-analysis examined the relationship between clonal haematopoiesis of indeterminate potential (CHIP) and epigenetic age acceleration (EAA) in a population of 7483 individuals aged 55-79.
Safety and efficacy of immune checkpoint inhibitors as a bridge to allogeneic hematopoietic stem cell transplantation in classical Hodgkin lymphoma: A systematic review and meta-analysis.
This systematic review and meta-analysis evaluated the safety and efficacy of immune checkpoint inhibitors (ICIs) as a bridge to allogeneic hematopoietic stem cell transplantation (allo-HCT) in patients with classical…
Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.
This phase 1 trial evaluated the long-term safety and efficacy of asciminib in 48 patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia (CML-CP).
False-positive HIV-1 RNA detection after CAR-T cell therapy in a multiple myeloma patient: multi-assay comparison confirms dual-target cross-reactivity.
A patient with multiple myeloma undergoing CAR-T cell therapy tested positive for HIV-1 RNA using two dual-target assays, showing low copy numbers.
Design, rationale, and baseline patient characteristics for the Sickle Cell Disease and CardiovAscular Risk-Red cell Exchange (SCD-CARRE) trial.
The Sickle Cell Disease and CardiovAscular Risk-Red cell Exchange (SCD-CARRE) trial is a randomized controlled trial assessing the impact of automated red blood cell exchange (RBCX) on health outcomes in 173 adults with…
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.
The TRIANGLE trial evaluated the impact of rituximab maintenance (RM) on progression-free survival (PFS) and overall survival (OS) in younger, untreated patients with mantle cell lymphoma (MCL) receiving…
Therapeutic drug monitoring guides personalized ponatinib dose reduction for chronic myeloid leukemia.
A 66-year-old woman with chronic-phase chronic myeloid leukemia was switched to ponatinib due to nilotinib-induced thrombocytopenia.
Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY-1 and MOMENTUM Trials.
These post hoc analyses of two phase 3 randomised trials examined how quickly patients with myelofibrosis and baseline hemoglobin < 10 g/dL achieved hemoglobin ≥ 10 g/dL with momelotinib, and whether this was associated…
Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up.
This nationwide Icelandic population-based screening study, which included a randomized trial of follow-up strategies, assessed clinical and psychological outcomes after monoclonal gammopathy screening.
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.
The phase III ENHANCE study evaluated the efficacy and safety of magrolimab plus azacitidine versus placebo plus azacitidine in treatment-naïve patients with higher-risk myelodysplastic syndromes.
Stay updated for free
Get the 3 most interesting publications in one specialty each week.
Weekly email. Unsubscribe anytime.
Want this personalized?
Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.
- Your specialties
- Your filters and thresholds
- Clinical Research + Case Reports, tuned separately
- Automatic weekly delivery
- Audio and text
Prefer listening? Personalized audio digests are available with Pro.